In preclinical development, Nodality has demonstrated that SCNP can assess compounds in heterogeneous cell populations such as whole blood, bone marrow, peripheral blood or bone marrow mononuclear cells, and solid tumor samples. By applying SCNP to physiologically relevant tissues, drug developers can determine IC50s in rare cells and inform off-target drug effects. This enables functional profiling for target selection and validation, activity measurement in different cell types, comparison of potency and selectivity with multiple drugs, as well as prediction of optimal dosing regimens in humans. SCNP technology can also be applied to animal models.
Click to enlarge